| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will be presenting both an oral presentation and a poster on VP-315, its oncolytic peptide for the treatment of basal cell carcinoma (BCC), at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting taking place November 5–9, 2025, in National Harbor, Maryland.
The abstract will be available on the SITC website on or about November 4, 2025, at 9 a.m. ET.
Oral and Poster Presentation Details:
Oral Presentation:
Abstract Number: 529
Presentation and Session Information:
Concurrent Session 205b: Rapid Oral Abstract Session - Clinical
12:15–1:15 p.m. ET | Gaylord National Resort and Convention Center - Ballroom Level - Maryland Ballroom CD
Co-Chairs: Kanika Jain, PhD – Ankyra Therapeutics & Abdul Rafeh Naqash, MD – Stephenson Cancer Center
Title: Exploratory analysis of a phase 2 multicenter study evaluating local immune activation in the tumor microenvironment 12 weeks post VP-315, an investigational therapy for basal cell carcinoma (BCC)
Presenter: Kenneth Y. Tsai, MD, PhD, Vice Chair, Research, Department of Pathology, Co-Director, Donald A. Adam Melanoma and Skin Cancer Center of Excellence, Moffitt Cancer Center
Time of Presentation: 12:46 - 12:54 p.m.
Poster Presentation:
Title: Exploratory analysis of a phase 2 multicenter study evaluating local immune activation in the tumor microenvironment 12 weeks post VP-315, an investigational therapy for basal cell carcinoma (BCC)
Authors: Kenneth Y. Tsai, MD, PhD1; David K. Glover ME, PhD2; Neal Bhatia MD3; Jonathan Weiss MD4; Megan Couvillion, MD5; Edward Lain, MD6; Daniel Carrasco, MD7; Benjamin Lockshin, MD8; Abel Jarell, MD9; Laura Ferris, MD10; Andrea Colton, MD11; Raina Agha, MD12; Cynthia Willson RN, BSN13; Thomas F. Haws13; Jayson Rieger PhD, MBA13; Pamela Rumney RN, CCRC13; Susan Cutler DMD13; Gary Goldenberg MD14, 15 Noah Rosenberg MD13
1. Moffitt Cancer Center, Tampa, FL; 2. PBM Capital Group, Charlottesville, VA; 3. Therapeutics Clinical Research, San Diego, CA; 4. Georgia Dermatology Partners and Gwinnett Clinical Research Center Inc., Snellville, GA; 5. Austin Institute for Clinical Research, Houston, TX; 6. Austin Institute for Clinical Research, Pflugerville, TX; 7. Austin Institute for Clinical Research, Dripping Springs, TX;8. Derm Associates, Rockville, MD; 9. Allcutis Research LLC, Portsmouth, NH; 10. Formerly at University of Pittsburgh Medical Center St. Margaret, Pittsburgh, PA; 11. Clearly Derm, Boca Raton, FL; 12. Affinity Health, Oakville, IL; 13. Verrica Pharmaceuticals Inc., West Chester, PA; 14. Assistant Clinical Professor, Dermatology, Icahn School of Medicine at Mount Sinai Hospital, NY, NY; 15. Formerly at Verrica Pharmaceuticals Inc., West Chester, PA.
Posted In: VRCA
